By recognising this key role of the BCR-ABL gene in CML development, it has thus been possible to devise tyrosine kinase inhibitors (TKI), that block ATP attachment, thereby inhibiting this enzyme’s activity [2–4]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.